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ABSTRACT
Alzheimer’s disease (AD) is the most common neurodegenerative disorder.  Along with an 
increasing  number  of  elderly  worldwide  it  poses  a  great  challenge  for  the  society  and 
healthcare. Although sporadic AD is the common form of AD, 2-3% of the AD cases are 
expected to be due to mutations in the beta region of the amyloid precursor protein which is 
referred to as autosomal dominant AD (ADAD).1 These mutations may cause changes in the 
secondary structure of the amyloid beta fibrils and may alter the fibrillization rate leading to 
changes  in  the  disease  development  and could  also  affect  the  binding to  tracers  used  in 
diagnosis.  In particular, from some recent clinical studies using PET tracers for detection of 
fibrillar amyloids it is evident that in ADAD patients with Arctic mutation no amyloid plaque 
binding can be detected with  11C-Pittsburgh Compound B  (11C-PIB). However, for in vitro 
conditions, significant binding of  3H-PIB has been reported for the amyloid fibrils carrying 
the Arctic mutation (Yamin et al. 2017). The aim of the present study is to investigate if there 
is  any mutation specific binding of commonly used amyloid tracers,  namely Florbetaben, 
Florbetapir, FPIB, AZD4694, AZD2184, by means of molecular modelling techniques. Other 
than Arctic, ADAD mutations, such as the Dutch, Italian, Iowa and Flemish mutations, are 
considered in this study. We report that all tracers except florbetapir show reduced binding 
affinity towards amyloid beta fibrils with the Arctic mutation when compared to the native 
type. Moreover, florbetapir is the only tracer that binds to all mutants with increased affinity 
when compared to the native fibril. The results obtained from these studies could increase the 
understanding of the structural changes, caused due by mutation and concomitant changes in 
the interaction pattern of the PET tracers with the mutated variants, which in turn can be 
useful in selecting the appropriate tracers for the diagnosis purpose as well as for designing 
new tracers with desirable properties. 
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INTRODUCTION
Alzheimer’s  disease  (AD)  is  the  most  common  form  of  dementia  as  well  as  a 
neurodegenerative  disorder.2  The  amyloid  (Aβ1-42)  deposits  remain  as  the  pathological 
hallmark  of  AD  and  the  Aβ  cascade  hypothesis  is  widely  accepted  by  the  scientific 
community.3 Molecular  imaging  enables  the  identification  of  Aβ  fibrils  in  vivo and  is 
clinically   used  in  the  diagnosis  of  AD.  Thus  the  three  PET tracers  18F-florbetapir,  18F-
florbetaben and  18F- flutemetamol (FPIB) have been approved by the US Food and Drug 
Administration and the European Medical Association (EMA) for use in clinical assessment 
of memory impairment to exclude AD.4 
Clinically, AD can be divided into early-onset (ie younger than 65 years) and late-
onset (ie, older than 65 years), whereas pathologically it is characterised by the presence of 
amyloid β peptide  plaques and intra-neuronal tangles of hyperphosphorylated forms of the 
tau protein (microtubule-associated protein tau, MAPT).5 Early-onset AD accounts for about 
5-10% of all AD cases among which 13% comprise the familial AD. These familial mutations 
can also be called autosomal dominant Alzheimer’s disease (ADAD) as they are occurring via 
autosomal dominant inheritance.6 In addition sporadic mutations in Alzheimer’s disease are 
also observed.
Some of the widely known  ADAD  mutations are  the Arctic, Italian, Dutch, Iowa 
and Flemish variants.7-11 It has been  observed from previous experimental studies that the 
rate of fibril formation generally increases  in those familial mutations, the  Flemish variant 
being an exception.12-16 Earlier  experimental studies have also  shown that the commonly 
occurring familial mutations  only marginally affect the predominant β-sheet conformation of 
the Aβ42 peptide,17 so that the basic β-sheet dominated structure of Aβ42 is retained in the 
mutated systems while the kinetics, i.e the rate of fibril formation, varies among the mutant 
systems with respect to the wild Aβ42. Apart from the above mentioned mutations many other 
types  of mutations referring to the amyloid precursor protein (APP) have been observed, 
however, they are present in the residues preceding the Aβ1-42 structural region and are mainly 
involved in the rate of formation of Aβ42 peptides which in turn affects the aggregation and 
consecutive effects.     
In vitro binding studies performed in autopsy brain tissue from ADAD and sporadic 
AD brain tissue have shown different binding properties of amyloid PET tracers such as 3H-
PIB, 3H-florbetaben and 11C-AZD2184 .18 In vivo PET studies with 11C-PIB have been unable 
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to demonstrate the fibrillar plaques in brain carriers of the Arctic form of early-onset AD.19 
However, in vitro studies on the binding of PIB (Pittsburgh compound -B) to wild type Aβ42 
and the Arctic  protofibril  has  also recently been published which  shows that  the  3H-PIB 
compound can bind to the protofibrils of Arctic Aβ42.20 The above observations illustrate the 
importance of understanding the interaction of commonly used PET tracers for Alzheimer’s 
disease with the different mutant structures of Aβ42.
Computational studies of the protein-ligand complexes have an innate advantage of 
obtaining molecular level information on the underlying interaction process which can be 
useful in interpreting the experimental observations. In order to have an atomistic picture of 
the  interaction  of  PET  tracers  with  different  mutations  in  Aβ42 we  have  carried  out  a 
modelling study using several ADAD mutations including the Arctic, Italian, Dutch, Iowa, 
Flemish mutations along with the native Aβ42 using the most widely used and experimentally 
studied PET tracers,  namely Florbetapir, Florbetaben, FPIB, AZD4694 and AZD2184. The 
reason for choosing these specific mutations is because in these cases the mutated residues 
are present in the Aβ42 structural regions which can directly influence the interaction with the 
PET tracers. It is notable that the Flemish mutation is considerably different from the other 
mutants in several ways; their neurotoxicity is slightly reduced   with respect to the native 
Aβ42;  their  fibrillization  rate  is  slower  compared  to  that  of  the  native  Aβ42;  they  are 
characterised by vascular deposition of the amyloid. We  included this system in our  study 
because  this  is  the  only  mutation  present  in  the  APP  structural  region  of  Aβ42 with 
considerably  contrasting  features  with  respect  to  native  Aβ42 in  comparison  to  the  other 
mutants.21   The variation in the mode of interaction between the various mutated amyloid 
peptides  and  different  PET  tracers  depends  on  few  important  factors  -  one  being  the 
conformational change induced by the mutated residue in the amyloid structure, a second 
factor is the direct involvement of the mutated residue on the interaction with the PET tracers 
and a third being that the structure of the PET tracer itself is favourable to some mutations 
and not favourable to other mutants. Thus the molecular level understanding on the stability 
of these complexes may shed light on some of the earlier results observed from in-vivo and 
clinical studies. We recall that the chemical accuracy of the currently available force-field 
methods  is  not  sufficient  to  distinguish  compounds  having  binding  affinity  in  the 
subnanomolar  range.  Free  energy  calculations  using  the  free  energy  perturbation  (FEP) 
approach has been reported with the standard error 0.6 kcal/mol while docking methods are 
associated with the range around 2.5 kcal/mol and these results are mostly system specific.22 
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The  molecular  mechanics  energies  combined with the generalized Born and surface area 
continuum solvation (MM/GBSA) method and  with molecular dynamics simulations (MD) 
is known to perform better than docking but is  known to sometimes underperform when 
compared  to  the  FEP approach.  A recent  study  by  Wang  and  co-workers  illustrate  that 
MM/GBSA is capable of capturing the experimental binding profile of various protein-ligand 
complexes similar in line with FEP methods despite the incorrect prediction of the binding 
mode for one of the ligands.23   The standard errors are known to be lower for biomolecular 
targets having rigid protein backbone and well defined binding sites. However, this has not 
been assessed in detail for targets with considerable flexibility like in the case of the amyloid 
beta  protofibrils.  Moreover,  the  absolute  value  of  the  binding  free  energy   has  little 
significance  in  force-field  methods  and  so  the  assessment  of  the  results  is  based  on the 
relative binding free energies when compared to a reference system (here native type amyloid 
beta fibril). In all, the MM/GBSA results here presented may be helpful in identifying the 
suitability  of  presently  used  PET tracers  in  detecting  the  amyloid  condition  in  different 
mutated variants of AD.  
RESULTS AND DISCUSSION
Docking
The three possible core docking sites on the Aβ42 fibril are illustrated in Figure 1 (we refer to 
the computational details section for further information about different core binding sites). 
The results of the docking carried out using the selected PET tracers onto the native and 
mutant variants of the Aβ42 peptide are presented in Table 1.  All five PET tracers seem to 
bind to all possible core binding sites except for three specific cases (AZD2184 in Italian 
mutation, AZD4694 and FPIB in Iowa mutation).  The docking energy values indicate that 
the S1 site was favourable for the native and mutant peptides in most of the cases irrespective 
of the PET tracers. In three specific cases, i.e florbetaben in Dutch mutation, florbetaben and 
AZD2184 in Iowa mutation, the S2 site is found to be ambiguously more favourable than the 
S1 site . 
We know from our previous studies that MD simulation results may vary from that of the 
docking  results  due  to  various  factors  such  as  solvation  and  protein  flexibility.24-26 We 
therefore cross checked our result of these ambiguous systems using MD. The results for 17 
nanosecond (ns) run are given in Table 2. It is found from the MD MM/GBSA results that the 
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S1  site  is  more  favourable  in  terms  of  energy  and  so  we  focussed  on  the  Aβ42-ligand 
complexes at the S1 site for the rest of the studies. 
Structural analysis
The different type of Aβ42 mutants used in this study and their details are presented in 
Table 3. As we are simulating the native Aβ42 and also their mutated systems it is essential to 
carry out structural analysis to understand the effect of mutation on the structural aspects of 
Aβ42 which can be compared with the previous experimental observations.17 Before doing the 
analysis, it is essential to assess whether the simulation is well equilibrated by means of a 
root  mean square deviation (RMSD) with respect  to  their  initial  structure.  The backbone 
RMSD of the peptide in various Aβ42 systems with different PET tracers was calculated and 
presented  in  Figure  2. The  results  indicate  that  most  of  the  simulated  systems  are  well 
equilibrated  and  saturated  with  RMSD  values  around  30  ns  with  the  exception  of  the 
Florbetapir -Aβ42 systems which are saturated around 40 ns. This shows that the time scale of 
the simulations is sufficient to attain equilibration for these complex systems. In accordance 
with the RMSD observation we used the last 10 ns of the trajectory for the MM/GBSA and 
secondary structure analysis to obtain meaningful results.
It is well established that the backbone hydrogen bonds are responsible for retaining 
the  beta  sheet  structure  of  the  Aβ42 peptide  assembly  making  it  essential  to  analyse  the 
backbone hydrogen bonding in the simulated system to have a view about the stability of the 
beta aggregate. The results of the backbone H-bonding in different systems with respect to 
time (see Figure 3) indicate that even though there is a fluctuation in the number of backbone 
H-bonds they are predominately consistent (averages around 30-35) throughout the course of 
the simulations. This illustrates that the fibril nature of the Aβ42 is retained for the various 
mutants. 
The secondary structure content of the Aβ42 in different systems for the last 10 ns of 
the simulation was calculated and tabulated in Table 4. The results indicate  that the beta 
content  of  Aβ42 varies  with  different  mutants  and  also  with  the  different  PET tracers. 
However, it is relevant to mention that the total beta content varies from a minimum of 38% 
to a maximum of 59 %. On the whole it is observed that the predominant beta fibril nature of  
Aβ42 is not affected by the mutation. An earlier in-vitro study regarding the aggregation of the 
Aβ42 and its different mutant peptides by Annelies et al also showed that the predominant beta 
nature of the peptide is retained.16 Thus it is understandable that the overall beta fibril nature 
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of the peptide is  retained even after  these  mutations.   As the fibril  nature of  Aβ 42 is  an 
essential requirement for the interaction of PET tracers, the predominant fibril nature of the 
mutations indicate that their interaction with PET tracers may be retained.  
MM/GBSA results
The experimental binding affinity of the PET tracers identified with the Aβ fibril were 
collected from literature and presented in the Table 5. These values are used as a guideline to 
check the binding affinities calculated using the MM/GBSA approach for the native system. 
It is important to mention that the experimental binding affinity results are provided in ranges 
of  values  obtained  from  different  experimental  measurements.  The  calculated  binding 
affinities of all the complexes are given in Table 6.  The results indicate that binding energy 
values of various PET tracers for the native system are in the range -20 to -28 kcal/mol 
explaining the nanomolar range binding affinity of these compounds. The calculated values 
generally reflect experimental observations with some differences that may be attributed to 
the use of Aβ1-40 in some cases of the experiments.  The overall  general consensus in the 
binding pattern can be reassured from the results of the native system.
The results indicate that all the PET tracers have a favourable binding energy with the 
native and mutant Aβ42 although there is some significant reduction in terms of magnitude in 
some specific cases. The interaction of thioflavin-t (THT)-like molecules, i.e. AZD4694 and 
AZD2168, with the mutant systems is weakened in all cases in comparison to the native one, 
except Iowa-AZD4694 where there is a slight increase of 3.4 kcal/mol. It is also noticeable 
that the gain in energy is due to the solvation component of the system whereas the direct 
interactions, van der Waals and electrostatic, are not much changed. It is also notable that the 
AZD2184 binding to the Flemish mutant is the weakest among all the systems with a mere 
8.5 kcal/mol binding energy owing to drastic reduction in terms of electrostatics and van der 
Waals energy.   As the Flemish mutant is considerably different from other mutants in terms 
of their neurotoxicity and fibrillation, it is notable that we here find that the Flemish mutants  
in general possess weaker binding affinities to the tracers among all the studied systems.  We 
also find that AZD4694 and AZD2184 bind to the mutant peptides satisfactorily even though 
there  is  a  slight  decrease  in  the  magnitude  of  interaction  energy  except  for  Flemish-
AZD2184.  The latter  has been reported to bind with high affinity in vitro both in sporadic 
and ADAD autopsy brain tissue.18 The in vitro binding data can be interpreted in such a way 
that although there is a decrease in the magnitude of interaction of AZD2184 to the mutant 
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peptide (except Flemish mutant) on comparing to the native system. In the case of ADAD, an 
increased  production  and  deposition  of  amyloid  plaques (except  Flemish  mutant)  which 
means a  larger  amount  of Aβ42 is  available  for  the PET binding that  might  explain why 
AZD2184 was found to have better binding affinity in vitro. It is also notable that the in vitro 
binding studies have been carried out with ADAD samples with mostly the Swedish and 
presenilin (PS1) mutations which cannot be compared with the different kind of structural 
mutations studied in this work.     
 The THT like molecule FPIB is illustrating similar trends for binding as that of AZD 
molecules. Also in case of FPIB it can be observed that the binding energy values of the 
mutant systems are reduced comparing to the native Aβ42 except the Dutch mutation in which 
there is a favourable interaction of around 2.8kcal/mol comparing to the native system. On 
the other hand, in all other mutants the reduction in the interaction energy is negligible with a 
maximum of 2.5kcal/mol. The results indicate that FPIB shows more or less the same kind of 
interaction with the native and mutant variants of Aβ42.  In vitro binding studies with 3H-PIB 
have also shown significant binding in autopsy ADAD brain tissues in agreement with the in-
silico results.18
The results of the MM/GBSA interaction energy of the different PET tracers under 
study with native and mutant variants of Aβ42 are illustrated in Figure 4. It is observed from 
the data that the stilbenoid-like molecules florbetaben and florbetapir in general show a better 
binding affinity to the mutated systems comparing to the THT-like molecules. For florbetapir 
a  higher  binding affinity was observed with all  the mutants compared to the native Aβ42 
systems where in the case of florbetaben there was a reduction in the binding affinity for the 
Arctic and Iowa mutations. In both the abovementioned cases the results indicate that the 
reduction in  energy is  due to  the van der  Waals  and electrostatic  components  as  well  as 
solvation  terms  of  the  interacting  complexes,  showing  that  the  florbetaben  tracer  is  less 
favourable for detection of these specific mutations.     
Residuewise contributions to the binding
The residuewise MM/GBSA energy contributions of each system are presented in 
Figure 5. This analysis can give insight about the role of each residue for the interaction 
between Aβ42 and  the  PET tracer.   The  illustrated  results  indicate  that  the  major  factors 
ambiguously driving the favourable interaction between the complexes are the hydrophobic 
residues  such  as  phenyl  alanine  and  valine.  In  our  previous  studies  we  stressed  the 
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importance of the NMR conformation 8 of 2BEG where the phenyl alanine core have the 
most  favourable  interaction  site.24-26  The  results  from  the  residue-wise  break  up  of  the 
MM/GBSA contribution  substantiate  our  earlier  findings:   In  the  case  of  florbetaben,  in 
addition to the phenylalanine and valine, the leucine residues make a significant contribution 
towards a favourable interaction. We observe from the plot that for Iowa-AZD4694 there is a 
stronger interaction of the phenyl alanine and valine residues compared to the native system 
which may explain the exceptional nature of this mutation in that it  has more favourable 
interaction  energy  than  the  native  system.  There  is  another  exceptional  case:  Arctic-
Florbetaben shows a significant decrease in the interaction energy with respect to the native 
system. A corresponding decrease in the contribution of key residues, such as phenyl alanine 
and valine, is observed for this complex when comparing with the native system.
As we are here dealing with the mutations involving three residues, namely alanine 
(A) 21, glutamic acid (E) 22 and aspartic acid (D) 23, of the Aβ42, it is important to monitor 
the contributions of these residues to the interaction energy. For this purpose we separately 
plotted the contributions of AED in the native Aβ42 i.e residues 21-23 (for all 5 chains) in all 
the systems separately and presented the results in Figure 6. This gives a closer view about 
the effect of these mutated residues in the interaction process.  In the earlier discussion we 
found that Dutch-FPIB has a favourable interaction which can be understood from the results 
for  the  mutated  residue  interaction  where  the  three  consecutive  AED  triads  favourably 
interact  with  FPIB  in  comparison  to  the  native  system.  Similarly,  we  also  observed  a 
reduction in the Arctic and Iowa mutations with florbetaben which is understood by analysing 
the mutated residue contributions. The plot in Figure 6 indicates that the native system has a 
more favourable energy contribution in terms of the 21-23 residues comparing with the Arctic 
and Iowa systems. In the case of Arctic–Florbetaben system, hydrophobic residues, such as 
phenyl  alanine,  valine,  and  the  residues  around  point  mutation  site  (residue  22)  are 
contributing to the increase in total binding free energy when compared to the native system. 
In  the  case  of  Flemish-AZD2184,  the  residues  around the  mutation  site  contribute  more 
favourably to the binding when compared to native fibril. This illustrates the predominance of 
the hydrophobic core residues in dictating the Aβ42-PET interaction process.   Thus it can be 
understandable from these results that a multitude of factors are responsible in determining 
the interaction process between  Aβ42 and PET tracers, some of the important ones are the 
conformation of the Aβ42 peptide and the  chemical nature of the ligand. In case of mutations 
further factors such as the conformational change induced by the mutation (which indirectly 
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leads  to  the  change  in  the  hydrophobic  core  residues  of  the  Aβ42)  as  well  as  the  direct 
interaction  of  the  mutated  residues  with  the  PET  tracer  also  play  important  roles  in 
determining the interaction pattern of atracer with Aβ42.      
Arctic mutation
In-vitro studies  of the Arctic  mutation show that  they are forming fibrils  whereas  earlier 
clinical studies  and pathological studies have shown Aβ plaques devoid of congophilic Aβ 
cores, indicating a lack of β-pleated sheet formation.17,19 A recent detailed postmortem study 
of plaque pathology associated with the APParc mutation reported the presence of C- and N-
terminally truncated forms of Aβ that are specific for the “Arctic” plaques.27 Clinical studies 
show that there is a low level of C-PIB retention in the case of Arctic mutation whereas 
recent in-vitro studies show that H-PIB can recognise the Arctic Aβ42 protofibril prepared in-
vitro and oligomers.19 Thus it seems to be a difference between the Arctic Aβ42 in the in-vitro 
condition and in the clinical form. 20 Our simulation results go along with the in-vitro results 
in that the Arctic mutants can form stable fibrils.  It will be important to have further details 
on the most dominant form of Aβ42 present in the case of Arctic AD and also its morphology 
under clinical condition in order to understand the peculiar behaviour of the Arctic case and 
appropriately understand the PET interaction.    
Conclusions
The aim of the present study was to find some underlying factors for the changes in the 
interaction pattern of PET tracers related   to mutation induced structural changes in amyloid 
fibrils which could be useful in selecting appropriate tracers for the diagnosis purpose and for 
designing new tracers with desirable binding properties.  The simulation results indicate that 
the familial mutations such as Dutch, Italian, Arctic, Iowa and Flemish do not change the 
predominant  fibril  nature  of  Aβ42 which  is  consistent  with  the  previous  experimental 
observations. The free energy values obtained for the mutated systems with the selected PET 
tracers show that in general the tracers can satisfactorily bind to the mutated Aβ42 systems 
except for a few cases such as the AZD2184-Flemish mutant and AZD4694 in the case of the 
Arctic and Flemish mutations in which there is a considerable reduction in the van der Waals 
and electrostatic energy components between the tracer and the Aβ42 peptide, implicating a 
worse compatibility of these tracers with the specific mutations.  In general the stilbenoid-like 
molecules florbetaben and florbetapir have a better binding affinity to the mutated systems 
comparing with the THT-like molecules AZD4694 and AZD2184. Florbetapir  is  found to 
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have better binding affinity with all the mutant systems under study with respect to the native 
system. Florbetaben is found to have better binding to the mutant systems except Arctic and 
Iowa cases, here also we find a significant reduction in the van der Waals and electrostatic 
energy components between the tracer and the Aβ42 peptide. The hydrophobic amino acids 
like phenyl alanine, valine, leucine and isoleucine are in general found to play a predominant 
role in the Aβ42-PET tracer interaction process. The direct interaction of the mutated residues 
with the PET tracers can also influence the binding affinity of the PET tracers to the mutated 
variants of Aβ42. The Arctic mutation is a peculiar case where there is a series of contradicting 
pieces  of  information  given  by  in-vitro and  clinical  studies  regarding  their  fibril  nature, 
morphology as well as N- and C- terminal truncations, thus making a further understanding 
on the Arctic mutation only possible from obtaining their clinically relevant structure.   The 
results  obtained from these studies can be useful  in  understanding the structural  changes 
caused by mutation and concomitant changes in the interaction pattern of the PET tracers 
with the mutated variants which in turn can be valuable for selecting the appropriate tracers 
for  the  diagnosis  purpose  as  well  as  for  designing  new  tracers  with  desirable  binding 
properties.        
COMPUTATIONAL DETAILS
Protein
The structure of Aβ42 from the protein data bank (PDB) with PDB ID 2BEG is taken as the 
proteins  structure  which  is  a  pentamer.28 It  is  well  established  that  the  amyloid  exist 
predominately in two forms Aβ40 and Aβ42, here we selected Aβ42 because this form is found 
to   play  an  important  role  in  the  amyloid  toxicity  and  they  are  found  in  increased 
concentrations in brains of patients with familial Alzheimer’s disease.29 It is known from the 
previous studies that the mutations such as Arctic, Italian, Dutch, Iowa and Flemish mutations 
differ from the wild type amyloid peptides in terms of aggregation kinetics but predominately 
the  beta  structure  is  preserved.  The sequence  of  the  native  Aβ42 along with  the  mutated 
variants with the specific amino acid mutation is shown in Scheme 1. The sites in the Aβ42 
residues which are mutated in the cases under study are shown in Figure 7. Based on the 
abovementioned  observation  the  coordinates  of  the  wild  type  structure  are  appropriately 
mutated with amino acid residues specific for each mutant to generate the initial structure. 
The Aβ42 has multiple binding sites for the tracers where they may be classified as surface 
binding sites and core binding sites.   In our previous studies it  was shown that  the core 
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binding sites are predominately dictating the tracer binding affinity trends so in this study we 
are restricting ourselves with the core binding sites.   Three possible core sites are identified 
where two sites are present in the first conformer NMR structure and the site specific to 
phenylalanine is present in eight conformers of the NMR structure.24-25 
Ligands
The PET tracers such as Florbetapir, Florbetaben, FPIB, AZD4694 and AZD2184 were used 
as  the  ligands  in  this  study.  Among these  five  ligands  the  first  three  ligands  have  been 
approved by FDA for clinical purpose.  The last  two have been studied earlier  with these 
mutant systems.  The chemical structure of the ligands under study is shown in Figure 8. 
Docking
The wild type Aβ42 structure is used as present in the NMR structure whereas in the case of 
the mutated Aβ42 the system is relaxed. In case of the mutated systems Aβ42 is equilibrated in 
Amber  14  using  FF99SBildn  parameters  with  12  Å  solvation  using  TIP3P  parameters 
(counterions were added to make the system neutral) at 300 K and 1atm pressure for 1ns.30-32 
The  systems  were  minimized  using  the  steepest  descent  algorithm  followed  by  the 
equilibration process in which the side chain of the mutated residues are free to relax whereas 
other atoms are restrained with weak force (10 kcal/mol Å2). The structure obtained from the 
equilibration process is used as the initial structure for docking in the case of mutant systems. 
All the possible core sites are explored for the interaction with different ligand molecules 
using docking. Since the amyloid protofibril does not have well defined binding sites, blind 
docking has been carried out using the autodock software.33 The grid box dimension has been 
chosen as 65X65X120 Å3 with grid size of 0.375 Å which is to make sure that all the core 
binding sites are identified. In particular, the docking has been carried out for the 1st and 8th 
conformers of amyloid protofibril and the mutant variants so that all core sites are used in the 
docking studies. 50 different low energy configurations for each ligand have been identified 
using the genetic algorithm and these configurations differ in terms of binding mode and 
binding pose in different binding sites.   The structures of the protein-ligand complexes with 
the least binding energy in different binding sites were considered for further analysis. 
Molecular dynamics simulations
Amber 14 package was used for the MD simulation. The low energy protein ligand docked 
complex is taken and are solvated with cubic box of TIP3P water molecules upto 12Å from 
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their outermost coordinates. Counterions were added to make the system neutral. FF99SBildn 
parameters  were  used  for  the  proteins  and  GAFF  parameters  were  used  for  the  ligand 
molecules (ESP charges using Gaussian (B3LYP/6-31G*) and Antechamber).34-36 The systems 
were minimized using the steepest  descent  algorithm followed by the equilibration using 
NVT and NPT ensemble 100ps each, the temperature of the system was raised from 0 to 
300K during NVT equilibration phase. The solute structure was constrained with a  weak 
force  (10kcal/mol  Å2)  in  the  energy  minimization  and  equilibration  steps.  Then  the 
production  run  of  50ns  in  NPT ensemble  was  carried  out  for  each  system without  any 
constraint.  The  temperature  of  the  system  was  maintained  at  300K  and  pressure  was 
maintained at 1 atm, respectively. A 12 Å cutoff was set for short-range interactions, while 
the electrostatic interactions beyond the cutoff were computed with the particle mesh Ewald 
(PME)  method.37 Bonds  involving  hydrogen  atoms  were  constrained  with  the  SHAKE 
algorithm.  A time step  of  2  fs  was  used,  and  the  trajectory  was  saved  every  2  ps.  The 
trajectories were visualized using the VMD and Pymol pograms.38-39 
Structural Analysis
The structural analysis  of the Aβ42 peptide from the simulated trajectory is carried out to 
monitor the structural changes induced in the Aβ42 due to the mutation. The root mean square 
deviation (RMSD) and number of backbone hydrogen bonds were calculated with respect to 
time. The secondary structural population of the peptide was calculated for the last 10 ns of 
the trajectory considering the first 40 ns as the equilibration time as the mutant systems have 
to evolve.  
Binding Free Energy Calculations
The  python  script  MMPBSA.py  of  Amber  14  was  used  to  do  Molecular 
Mechanics/Generalized Born Surface Area (MM/GBSA) calculations,40 which can be used to 
calculate the binding free energies of ligand with native Aβ42 and other mutant fibrils. The 
data from the last 10 ns of the MD trajectories were used for MM/GBSA calculations in the 
single trajectory mode; namely, the snapshots of ligand, protein, and complex were extracted 
from the same trajectory (once in 50 frames). This mode was efficient and has been used 
extensively in binding free energy calculations.41 The average values and standard errors were 
calculated from the results of all the extracted snapshots. The residuewise contribution of 
MM/GBSA was also calculated for each system.
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Supporting Information:
The individual  comparative plots  of RMSD and number of H-bonds of all  the simulated 
systems are presented for clarity purpose. 
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Table 1.  The results of various PET tracers docked with the core binding sites of the wild 
type and mutant Aβ42 systems (energy in kcal/mol).  
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S.No Tracer S1 S2 S3
Native
1 Florbetaben -8.14 -8.01 -7.74
2 Florbetapir -7.90 -7.68 -7.45
3 FPIB -8.66 -8.13 -7.05
4 AZD4694 -8.62 -8.04 -7.48
5 AZD2184 -8.44 -7.97 -6.82
Arctic
6 Florbetaben -8.05 -7.54 -7.46
7 Florbetapir -7.85 -7.54 -7.51
8 FPIB -8.62 -8.19 -6.83
9 AZD4694 -8.60 -7.96 -7.22
10 AZD2184 -8.40 -8.17 -6.56
Italian
11 Florbetaben -7.84 -7.71 -6.67
12 Florbetapir -7.40 -6.99 -6.92
13 FPIB -8.34 -7.90 -5.82
14 AZD4694 -8.32 -8.30 -6.51
15 AZD2184 -8.22 -8.18 -
Dutch
16 Florbetaben -7.07 -7.33 -7.07
17 Florbetapir -7.04 -7.01 -6.87
18 FPIB -8.25 -7.78 -6.69
19 AZD4694 -8.37 -7.74 -7.41
20 AZD2184 -8.11 -7.72 -6.93
Iowa
21 Florbetaben -7.37 -7.67 -5.89
22 Florbetapir -7.33 -7.03 -6.07
23 FPIB -8.29 -7.87 -
24 AZD4694 -8.45 -7.99 -
25 AZD2184 -7.99 -8.20 -7.26
Flemish
26 Florbetaben -8.39 -6.94 -7.91
27 Florbetapir -9.34 -7.85 -8.58
28 FPIB -8.31 -7.95 -7.66
29 AZD4694 -8.11 -8.22 -7.61
30 AZD2184 -8.86 -8.15 -8.16
Table 2. MM/GBSA calculated binding affinities (ΔGbind) of selected system at the S1 and S2 
binding sites (energy in kcal/mol).
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Figure 1. Schematic representation of the three possible core binding sites in the Aβ42 peptide.
Table 6.  MM/GBSA calculated binding affinities of different PET-Aβ42 complexes (energy in 
kcal/mol).
S.No System ∆EVdw   ∆Eelec ∆GGB ∆GSASA T∆S ΔGbind ∆∆Gbind
Native        
1 Florbetaben -56.01±0.24 -15.51±0.40 27.99±0.38 -7.80±0.02 -23.44±0.52 -27.91 -
2 Florbetapir -50.36±0.35 -3.64±0.20 15.48±0.19 -6.54±0.04 -24.00±0.52 -21.06 -
19
3 FPIB -46.69 ±0.22 -5.81 ±0.38 15.81 ±0.31 -4.90 ±0.01 -21.12±0.47 -20.48 -
4 AZD4694 -41.87±0.23 -15.12±0.36 24.48±0.31 -4.62±0.01 -17.13±0.52 -20.00 -
5 AZD2184 -45.57±0.22 -17.70±0.27 25.91±0.18 -4.34±0.01 -17.91±0.52 -23.80 -
Arctic
6 Florbetaben -46.40±0.07 -7.12±0.08 15.36±0.05 -6.26±0.01 -25.63±0.37 -18.80  9.11
7 Florbetapir  -58.41±0.36 -11.11±0.34  22.74±0.33 -6.82±0.03 -26.65±0.45 -26.94 -5.88
8 FPIB -45.33±0.07 -4.89±0.12 16.41±0.12 -4.88±0.01 -19.70±0.38 -19.00  1.48
9 AZD4694 -36.81±0.06 -2.99±0.09 12.72±0.08 -4.16±0.01 -17.85±0.04 -13.40  6.60
10 AZD2184 -41.99±0.21 -10.21±0.28 18.26±0.21 -4.94±0.01 -18.64±0.23 -20.24  3.56
Italian
11 Florbetaben -61.92±0.08 -6.19±0.11 17.93±0.09 -7.50±0.01 -25.10±0.57 -32.58   -4.67
12 Florbetapir -58.80±0.34 -16.37±0.39 24.61±0.28 -6.95±0.01 -23.01±0.52 -33.71 -12.65
13 FPIB -41.64±0.07 -10.98±0.07 18.93±0.05 -4.89±0.00 -18.71±0.43 -19.87     0.61
14 AZD4694 -42.23±0.08 -6.31±0.13 15.52±0.08 -4.49±0.00 -20.06±0.45 -17.45     2.55
15 AZD2184 -42.84±0.23 -17.93±0.22 25.34±0.19 -4.53±0.01 -17.61±0.63 -22.35    1.45
Dutch
16 Florbetaben -56.16±0.11 -9.15±0.09 19.16±0.08 -7.06±0.01 -24.99±0.49 -28.22 -0.31
17 Florbetapir -63.84±0.29 -4.93±0.18 15.48±0.23 -7.99±0.01 -26.25±0.42 -35.04 -13.98
18 FPIB -42.57±0.06 -5.88±0.06 14.34±0.05 -4.86±0.00 -15.74±0.50 -23.23 -2.75
19 AZD4694 -39.64±0.06 -8.56±0.10 17.58±0.07 -4.42±0.00 -18.71±0.31 -16.34  3.66
20 AZD2184 -41.01±0.22 -10.44±0.20 17.90±0.13 -4.61±0.01 -20.78±0.46 -17.38    6.42
Iowa
21 Florbetaben -51.23±0.10 -10.69±0.08 19.13±0.06 -6.61±0.01 -24.59±0.36 -24.81 3.10
22 Florbetapir -54.43±0.31 -14.90±0.39 25.16±0.28 -7.20±0.02 -25.94±0.54 -25.44 -4.38
23 FPIB -41.09±0.07 -15.96±009 23.04±0.05 -4.84±0.00 -19.94±0.43 -18.92 1.56
24 AZD4694 -40.28±0.07 -15.19±0.11 18.60±0.05 -4.73±0.11 -18.24±0.53 -23.37   -3.37
25 AZD2184 -45.38±0.26 -11.10±0.40 22.88±0.30 -4.77±0.01 -18.86±0.48 -19.52  4.28
Flemish
26 Florbetaben -51.28±0.10 -16.00±0.15 23.51±0.12 -7.33±0.01 -24.66±0.49 -26.44 1.47
27 Florbetapir -48.76±0.32 -12.77±0.34 24.64±0.33 -6.27±0.03 -20.38±0.62 -22.78 -1.72
28 FPIB -42.60±0.09 -6.36±0.15 19.41±0.16 -4.89±0.01 -16.47±0.50 -17.98  2.50
29 AZD4694 -36.35±0.12 -3.68±0.08 11.90±007 -4.34±0.00 -17.72±0.64 -14.76 5.24
30 AZD2184 -34.06±0.19 -3.05±0.26 13.58±0.19 -3.85±0.02 -18.88±0.30 -8.51  15.29
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Figure 2.  The root mean square deviation 
(RMSD) of the Aβ42 peptide in the different 
Aβ42-PET tracer systems simulated.
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Figure 3.  The number of back bone hydrogen bonds present in the Aβ42 peptide in the 
different Aβ42-PET tracer systems simulated.
22


Figure 6. The residue wise contribution of 
the mutated amino acid present in the Aβ42 
system towards the MM/GBSA binding free 
energy in the different Aβ42-PET tracer 
systems.
25

Florbetaben
Florbetapir
FPIB
AZD4694
AZD2184
Figure 8. The structure of different PET tracers used in this study.
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